LCM
ANIK icon

Legato Capital Management’s Anika Therapeutics ANIK Stock Holding History

Legato Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,556
Closed -$217K – 575
2023
Q1 		$217K Hold
7,556
– – 0.04% 440
2022
Q4 		$224K Buy
+7,556
New +$215K 0.04% 436

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legato Capital Management's ANIK Position: Q2 2023 in Review

Legato Capital Management sold out of Anika Therapeutics (ANIK) in Q2 2023, closing a stake of 7,556 shares — an estimated $217K sold.

Legato Capital Management first reported a position in ANIK in Q4 2022 and held it in 2 quarters. The position peaked at $224K in Q4 2022. 117 funds tracked by Wall St. Rank hold ANIK as of Q2 2023.

  • Legato Capital Management reported no remaining Anika Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Legato Capital Management sold 7,556 Anika Therapeutics shares in Q2 2023, an estimated $217K.
  • Legato Capital Management first reported a position in Anika Therapeutics in Q4 2022 and held it in 2 quarters.
  • Legato Capital Management's Anika Therapeutics position peaked at $224K in Q4 2022.
  • 117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2023.

Based on Legato Capital Management's 13F filing for Q2 2023, filed 18 Aug 2023.